This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

MedTech Summit

Early Registration Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Hybrid Event, 20 - 24 June 2022
In-Person: Clayton Hotel Burlington Road, Dublin, IrelandDigital Experience: One track will be live-streamed each day in BST time zone, with on-demand recording access for all other tracks made available from the afternoon of the following day. Learn more on the Digital Experience page.

Prasad Peri
Senior Director Global Regulatory Affairs CMC (Small Molecules, Biologics, and Combination Products) at Teva Pharmaceuticals


S. Prasad Peri is a Senior Director, Global Specialty Regulatory Affairs CMC at Teva Branded Pharmaceutical Products R&D Inc., based in West Chester, PA. He and his team are responsible for the US Regulatory CMC strategy for Small Molecules, Biologics, Combination Products and Devices. Prior to joining Teva, Prasad Peri was at Merck and Co. USA as a Director for Global Regulatory Affairs CMC responsible for Combination products and Devices. Prior to joining Merck, Prasad Peri held the position of a Branch Chief at the Office of New Drug Quality Assessment within FDA responsible for the CMC review assessment of products submitted to Divisions of Pulmonary, Allergy, Rheumatology, Anesthesia, Analgesia and Addiction. Prasad Peri holds a Ph.D. in Pharmaceutical Chemistry and a BS in Pharmacy.

Agenda Sessions

  • Status Transition from Drug to Device: An Update from the United States